Carolyn Muller, MD
Gynecologic Oncology · Albuquerque, NMNPI 1598772550
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,120 of the $6,399 with a category attached, or 95.6%. GSK accounts for 64.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $5,385 and has fallen 82.2% since, to $957 in 2025.
Across 11 payments — averaging $581.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Seagen Inc.$1K
- Eli Lilly$957
- Merck$33
- Sanofi Pasteur Inc.$25
- Clovis Oncology, Inc.$10
Across 79 payments — averaging $6846.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$433K
- Genmab U.S., Inc.$36K
- Incyte Corporation$29K
- AbbVie$21K
- Pfizer$18K
- Seagen Inc.$3K
- plus $2K from 1 others
What the payments were for
- Consulting fees$6,12096%
- Food & beverage$2364%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $4,154 |
| Seagen Inc. | 1 | $1,220 |
| Eli Lilly | 2 | $957 |
| Merck | 3 | $33 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEMPERLI$4,000
How this compares
Too few gynecologic oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 13 | $36 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Albuquerque
- Luis Padilla PazAlbuquerque$99K
- Stephanie RiederAlbuquerque$76K
- Ketura WisnerAlbuquerque$23K
- Karen FinkelsteinAlbuquerque$16K
- Amaranta CraigAlbuquerque$8K
- Joel WebbAlbuquerque$5K
- Leo TwiggsAlbuquerque$3K
- Sarah AdamsAlbuquerque$521
- Katijane DexterAlbuquerque$510
- Teresa RutledgeAlbuquerque$195
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.